Literature DB >> 29285393

Chronic myeloid leukemia following liver transplantation: A case report.

Ling Zhang1, Bing Long1, Xiao-Qing Li1, Zhi-Gang Fang1, Wen-Xing Lai1, Dong-Jun Lin1.   

Abstract

Long-term utilization of immunosuppression in organ transplant recipients leads to decreased immune-mediated tumor surveillance and increased risk of developing malignant tumors. However, chronic myeloid leukemia (CML) following living donor liver transplantation (LDLT) is rarely reported. The current case report presents a 42-year-old male patient who developed CML 14 months following LDLT. The patient achieved complete hematologic remission and early molecular response at 3 months imatinib treatment and major molecular response at 12 months imatinib treatment. The pathogenesis, risk factors, treatment and prognosis for CML following liver transplantation are unclear. Therefore, further analysis through accumulation of cases will be of great importance to prevent and treat this rare complication following liver transplantation.

Entities:  

Keywords:  chronic myeloid leukemia; immunosuppression; liver transplantation

Year:  2017        PMID: 29285393      PMCID: PMC5740856          DOI: 10.3892/mco.2017.1465

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  15 in total

1.  Posttransplant malignancies.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

Review 2.  Posttransplantation malignancies: a problem, a challenge, and an opportunity.

Authors:  H Myron Kauffman; Wida S Cherikh; Yulin Cheng
Journal:  Liver Transpl       Date:  2002-05       Impact factor: 5.799

3.  Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.

Authors:  Xiu-Feng Yin; Jing-Han Wang; Xia Li; Meng-Xia Yu; Zhi-Xin Ma; Jie Jin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-06-08

4.  Two cases of post-liver transplant acute myeloid leukemia in Korean adults: review of bibliographies and comparison with post-renal transplant acute myeloid leukemia.

Authors:  Young-Uk Cho; Hyun-Sook Chi; Chan-Jeoung Park; Eul-Ju Seo; Je-Hwan Lee; Jung-Hee Lee; Sung-Gyu Lee
Journal:  Ann Hematol       Date:  2008-02-26       Impact factor: 3.673

5.  Chronic myeloid leukemia after living donor liver transplantation.

Authors:  Allan Concejero; Chao-Long Chen; Chih-Chi Wang; Shih-Ho Wang; Chih-Che Lin; Yueh-Wei Liu; Chin-Hsiang Yang; Chee-Chien Yong; Ming-Chung Wang; Hock-Liu Eng
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

6.  T-cell acute lymphoblastic leukaemia after liver transplantation: post-transplant lymphoproliferative disorder or coincidental de novo leukaemia?

Authors:  Yanan Fang; Kerice A Pinkney; John C Lee; Tatyana Gindin; Michael A Weiner; Bachir Alobeid; Govind Bhagat
Journal:  Hematol Oncol       Date:  2012-05-22       Impact factor: 5.271

7.  A case report of acute myeloid leukemia after liver transplantation.

Authors:  Mingjuan Liu; Ji Liu; Lihui Liu; Li Yu; Bing Shi; Liping Ye; Yongqing Zhang; Hu Chen
Journal:  Acta Haematol       Date:  2013-01-05       Impact factor: 2.195

8.  Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.

Authors:  Mehmet Gündüz; Mehmet Özen; Uğur Şahin; Selami Koçak Toprak; Sinem Civriz Bozdağ; Meltem Kurt Yüksel; Önder Arslan; Muhit Özcan; Taner Demirer; Meral Beksaç; Osman İlhan; Günhan Gürman; Pervin Topçuoğlu
Journal:  Clin Transplant       Date:  2017-05-25       Impact factor: 2.863

9.  Acute Philadelphia chromosome-positive leukemia in an adolescent boy after liver transplantation.

Authors:  Christopher C Silliman; R Weslie Tyson; Qi Wei; Frederick G Karrer; Stella M Davies; Marilyn Blake; Loris McGavran
Journal:  J Pediatr Hematol Oncol       Date:  2003-07       Impact factor: 1.289

10.  BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.

Authors:  Philipp le Coutre; Petra Reinke; Ruth Neuhaus; Ralf Trappe; Frauke Ringel; Marc Lalancette; Philipp G Hemmati; Bernd Dörken; Peter T Daniel
Journal:  Eur J Haematol       Date:  2009-10-03       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.